Literature DB >> 8627583

Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.

W Y Chan1, N C Wo, L L Cheng, M Manning.   

Abstract

Substitution of Asn5 in oxytocin (OT) or vasopressin (VP) invariably leads to a dramatic loss of the biological activities of the peptides. Because of this observation, few structure-activity-relationship studies of OT and VP peptides have involved modifications in the 5 position. It is now recognized that peptide agonists and antagonists may use different structural and conformational features in their interactions with the receptors. Our prior studies showed that OT and VP antagonists, unlike the agonists, tolerate amino acid substitutions in the 5 position. This opens new approaches for the design of antagonists. We describe the effects of isosteric replacement of Asn5 by diaminopropionic acid (Dap) or diaminobutyric acid (Dab) in three OT and VP antagonists: (1) the V1a (vasopressor receptor) antagonist d(CH2)5[Tyr(Me)2]AVP; (2) the OT (uterine OT receptor) antagonist d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH29] OVT and (3) three selective OT antagonists, desGly-NH2,d(CH2)5[D-Tyr2, Thr4]OVT, desGly-NH2, d(CH2)5[D-Phe2, Thr4]OVT and desGly-NH2, d(CH2)5- [D-Trp2, Thr4]OVT. The Dap5 and Dab5 substitutions were tolerated remarkably well, with the less isosteric Dap5 substitution leading to a greater retention of anti-OT potency than the Dab5 substitution. Furthermore, the Dap5 and Dab5 and OT and VP antagonist analogues were surprisingly shown to be much more selective than their respective parent compounds. The Dab5 analogue of (1) was devoid of anti-OT activity. The three Dap5 analogues of (3) were devoid of anti-V1a activities. These appear to be the first single-receptor-type-selective OT and VP antagonists discovered to date. These findings could provide new leads for the development of single-receptor-type-selective receptor probes for the localization and characterization of OT and VP receptors and potential selective tocolytics for the treatment of premature labor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627583

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Direct stimulatory effects of oxytocin in female rat gonadotrophs and somatotrophs in vitro: comparison with lactotrophs.

Authors:  Arturo E Gonzalez-Iglesias; Patrick A Fletcher; José A Arias-Cristancho; Ruth Cristancho-Gordo; Cleyde V Helena; Richard Bertram; Joël Tabak
Journal:  Endocrinology       Date:  2014-11-19       Impact factor: 4.736

2.  Vasopressin Increases Urinary Acidification via V1a Receptors in Collecting Duct Intercalated Cells.

Authors:  Torsten Giesecke; Nina Himmerkus; Jens Leipziger; Markus Bleich; Taka-Aki Koshimizu; Michael Fähling; Alina Smorodchenko; Julia Shpak; Carolin Knappe; Julian Isermann; Niklas Ayasse; Katsumasa Kawahara; Jan Schmoranzer; Niclas Gimber; Alexander Paliege; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2019-05-16       Impact factor: 10.121

3.  Sex differences in vasopressin 1a receptor regulation of social communication within the lateral habenula and dorsal raphe of mice.

Authors:  Nicole Rigney; Rachael Beaumont; Aras Petrulis
Journal:  Horm Behav       Date:  2020-03-10       Impact factor: 3.587

4.  Septal oxytocin administration impairs peer affiliation via V1a receptors in female meadow voles.

Authors:  Allison M J Anacker; Jennifer D Christensen; Elyssa M LaFlamme; Diana M Grunberg; Annaliese K Beery
Journal:  Psychoneuroendocrinology       Date:  2016-02-26       Impact factor: 4.905

5.  Central actions of arginine vasopressin and a V1a receptor antagonist on maternal aggression, maternal behavior, and grooming in lactating rats.

Authors:  Benjamin C Nephew; Robert S Bridges
Journal:  Pharmacol Biochem Behav       Date:  2008-06-29       Impact factor: 3.533

Review 6.  Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Authors:  M Manning; A Misicka; A Olma; K Bankowski; S Stoev; B Chini; T Durroux; B Mouillac; M Corbani; G Guillon
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

7.  Plasticity and Function of Spinal Oxytocin and Vasopressin Signaling during Recovery from Surgery with Nerve Injury.

Authors:  Amie L Severino; Rong Chen; Kenichiro Hayashida; Carol A Aschenbrenner; Haiguo Sun; Christopher M Peters; Silvia Gutierrez; Bethany Pan; James C Eisenach
Journal:  Anesthesiology       Date:  2018-09       Impact factor: 8.986

8.  Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design.

Authors:  Johannes Koehbach; Margaret O'Brien; Markus Muttenthaler; Marion Miazzo; Muharrem Akcan; Alysha G Elliott; Norelle L Daly; Peta J Harvey; Sarah Arrowsmith; Sunithi Gunasekera; Terry J Smith; Susan Wray; Ulf Göransson; Philip E Dawson; David J Craik; Michael Freissmuth; Christian W Gruber
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.